A Phase I, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of IDX719 in Subjects With Normal and Impaired Hepatic Function
Latest Information Update: 12 May 2022
At a glance
- Drugs Samatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 12 Mar 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 12 Aug 2013 New trial record